In response to press reports calling into question the quality of the US drug supply, FDA Commissioner Gottlieb and CDER Director Janet Woodcock explained some of the fundamental steps taken to protect the quality and effectiveness of generic medicines and addressed perceived shortcomings in the analyses performed by some news outlets.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
